Compare DexCom, Inc. (DXCM) vs Sezzle Inc (SEZL) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

Sezzle (SEZL) trades at $193.51, up 6.1% today and approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and trades above key resistance at $194. Fundamentally, the company demonstrates impressive profitability with 30.83% net margins and 91.95% ROE, supported by consistent earnings beats in recent quarters. Recent news highlights product expansion and raised 2026 guidance following strong Q1 results.

Outlook remains positive with accelerating revenue growth and expanding profitability, though valuation multiples appear elevated. Key risks include competitive pressures in fintech and ongoing securities investigation. Analyst consensus is split with 50% buy ratings but average price target of $162 suggests caution about current valuation levels.